Streptozocin is a last resort anti-tumor agent commonly used to treat metastatic cancer of pancreatic islet cells. Streptozocin is freely soluble in aqueous solution (>100 mg/mL).
|Mechanism of Action||Streptozocin acts as an alkylating agent which damages DNA by adding methyl and other alkyl groups which interfere with normal base pairing.|
|Impurity Profile||α-isomer: ≥75.0%|
Residue on Ignition: ≤0.1%
Heavy Metals: ≤20ppm
|Eukaryotic Cell Culture Applications||Streptozocin is frequently used to induce diabetes and insulitis for diabetes research in mamalian models.|
TOKU-E streptozocin was used in a study by Xufeng Yang et al. : Effects of Radix Linderae extracts on a mouse model of diabetic bladder dysfunction in later decompensated phase
|Cancer Applications||Streptozocin has shown to decrease tumor size and relevant tumor-induced symptoms including hypoglycemia.|
Murray-Lyon IM, Eddleston AL, Williams R, Brown M, Hogbin BM, Bennett A, Edwards JC, Taylor KW (1968). "Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin". Lancet 2 (7574): 895–8.
Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients . Ann Intern Med 1973;79:108–18.
Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma . N Engl J Med 1980;303:1189–94.